“We are pleased by these findings, which together with the recently reported positive top-line results from our second Phase 3 trial, encourage us that, if approved, abrocitinib may provide the first oral, once-daily treatment option for these patients,” stated Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Stay Informed! Stay Competitive! Join us at Vista Partners! It’s FREE to receive email updates. oct2(1)
Pfizer Shares Results Of Phase 3 Data For Abrocitinib In Moderate To Severe Atopic Dermatitis
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib), and cetuximab (BRAFTOVI Triplet) with patients suffering from advanced BRAFV600E-mutant metastatic colorectal cancer. Pfizer announced results from a phase 3, 12-week, pivotal study in patients from 12 years and above with Abrocitinib at the 28th Congress of the European Academy of Dermatology and Venereology (EADV) that took place on October 9-13, 2019 in Madrid, Spain. Abrocitinib, an investigational oral Janus kinase 1 inhibitor fulfilled all the co-primary and secondary endpoints relating to skin clearance and itch relief in comparison to placebo. The doses of abrocitinib (200mg and 100mg) were well accepted. In JADE MONO-1 the co-primary study endpoints were the proportion of patients who achieved score of clear to almost clear skin score, as per Global Assessment (IGA) to the proportion of improvement of at least 75% or greater from baseline in their Eczema Area. The secondary endpoints were the number of patients who achieved point four or significant reduction in their itch severity measured with the pruritus numerical rating scale along with the magnitude of decrease PSAAD.
Post View Count : 1037